BioLife Solutions, Inc.
BLFS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $82,254 | $143,271 | $76,239 | $119,156 |
| % Growth | -42.6% | 87.9% | -36% | – |
| Cost of Goods Sold | $28,583 | $96,519 | $107,937 | $81,408 |
| Gross Profit | $53,671 | $46,752 | $53,822 | $37,748 |
| % Margin | 65.3% | 32.6% | 70.6% | 31.7% |
| R&D Expenses | $7,912 | $18,796 | $14,798 | $11,819 |
| G&A Expenses | $40,541 | $55,725 | $47,670 | $34,097 |
| SG&A Expenses | $50,151 | $80,308 | $69,240 | $48,093 |
| Sales & Mktg Exp. | $9,610 | $12,709 | $11,672 | $13,996 |
| Other Operating Expenses | $2,737 | $18,473 | $9,696 | $8,202 |
| Operating Expenses | $60,800 | $117,577 | $93,734 | $68,114 |
| Operating Income | -$7,129 | -$70,825 | -$5,923 | -$35,160 |
| % Margin | -8.7% | -49.4% | -7.8% | -29.5% |
| Other Income/Exp. Net | -$4,296 | $4,969 | $1,075 | $6,134 |
| Pre-Tax Income | -$11,425 | -$66,258 | -$4,848 | -$29,026 |
| Tax Expense | -$38 | $169 | -$5,236 | -$20,118 |
| Net Income | -$20,184 | -$66,427 | -$139,805 | -$8,908 |
| % Margin | -24.5% | -46.4% | -183.4% | -7.5% |
| EPS | -0.44 | -1.52 | -3.29 | -0.23 |
| % Growth | 71.1% | 53.8% | -1,330.4% | – |
| EPS Diluted | -0.44 | -1.52 | -3.29 | -0.23 |
| Weighted Avg Shares Out | 46,067 | 43,719 | 42,481 | 38,504 |
| Weighted Avg Shares Out Dil | 46,067 | 43,719 | 42,481 | 38,504 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $719 | $1,812 | $687 | $485 |
| Depreciation & Amortization | $8,661 | $12,295 | $19,958 | $12,865 |
| EBITDA | $1,532 | -$45,238 | -$124,182 | -$16,654 |
| % Margin | 1.9% | -31.6% | -162.9% | -14% |